You are here

CG Oncology

Biopharma IPOs From the First Half of 2024

BioSpace

Thu, 05/30/24 - 11:17 am

Kyverna Therapeutics

ArriVent Biopharma

Alto Neuroscience

Contineum Therapeutics

Rapport Therapeutics

Telix Pharmaceuticals

CG follows big IPO with new results for bladder cancer drug

BioPharma Dive

Sun, 05/5/24 - 11:35 pm

Fierce Biotech's Quarterly IPO and M&A Roundup: Q1'24

Fierce Biotech

Wed, 04/3/24 - 11:36 am

Kyverna Therapeutics

Contineum Therapeutics

CymaBay Therapeutics

Gilead Sciences

Fusion Pharmaceuticals

Everyone's Talking About These 2 Biotech IPO Stocks

Motley Fool

Sun, 02/25/24 - 08:55 pm

Kyverna Therapeutics

CG Oncology prices larger-than-expected $380M IPO in hopeful sign for biotech

BioPharma Dive

Wed, 01/24/24 - 11:36 pm

2024 Brings Surprising Early Surge of Biotech IPOs

BioSpace

Fri, 01/19/24 - 09:43 am

Alto Neuroscience

ArriVent Biopharma

Kyverna Therapeutics

CG Oncology aims for $209M IPO, as more biotechs eye path to public markets

Fierce Biotech

Thu, 01/18/24 - 11:11 am

CG Oncology plans IPO plunge ahead of phase 3 bladder cancer drug readout

Fierce Biotech

Wed, 01/3/24 - 09:35 am

In a year with few biotech IPOs, ‘crossover’ financings are hard to find

BioPharma Dive

Wed, 08/16/23 - 10:00 am

crossover financing

CG brings back the crossover round, reeling in $105M to fund phase 3 bladder cancer trial

Fierce Biotech

Wed, 08/2/23 - 11:30 am

clinical trials

#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets

Endpoints

Mon, 06/6/22 - 10:31 am

Oncolytic immunotherapy biotech CG Oncology nabs $47M round for late-stage cancer push

Fierce Biotech

Fri, 12/11/20 - 11:11 am